Biopterin and neurotransmitter amine metabolism in children with acute lymphoblastic leukemia receiving methotrexate therapy

Pinkerton, CR, Smith, I, Leeming, RJ, Sarna, G, Hyland, K, Curzon, G and Chessells, JM (1986) Biopterin and neurotransmitter amine metabolism in children with acute lymphoblastic leukemia receiving methotrexate therapy. The Journal of Pediatrics, 108 3: 470-474. doi:10.1016/S0022-3476(86)80904-0


Author Pinkerton, CR
Smith, I
Leeming, RJ
Sarna, G
Hyland, K
Curzon, G
Chessells, JM
Title Biopterin and neurotransmitter amine metabolism in children with acute lymphoblastic leukemia receiving methotrexate therapy
Journal name The Journal of Pediatrics   Check publisher's open access policy
ISSN 0022-3476
Publication date 1986-01-01
Year available 1986
Sub-type Article (original research)
DOI 10.1016/S0022-3476(86)80904-0
Open Access Status Not Open Access
Volume 108
Issue 3
Start page 470
End page 474
Total pages 5
Publisher MOSBY-ELSEVIER
Language eng
Subject 2735 Pediatrics, Perinatology, and Child Health
Abstract To test the hypothesis that some of the neurologic sequelae of treatment for acute lymphoblastic leukemia (ALL) might be related to abnormalities in biopterin metabolism associated with methotrexate (MTX) therapy, total biopterin levels in cerebrospinal fluid (CSF) and plasma, and homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) were measured in a cross-sectional study of 80 children with ALL. For comparison, biopterins were also measured in a group of children of similar age undergoing investigation for neurologic disease. In children with ALL studied before therapy, no significant difference was found between the means of plasma biopterin of CSF biopterin concentrations and the means in the control group. In children receiving MTX, plasma biopterin values were higher in the group given maintenance therapy than in children observed before treatment. CSF levels were significantly increased only in those patients who had completed 2 years of maintenance therapy. CSF concentrations of HVA and 5HIAA in patients with ALL who had received no treatment (median values 52 and 18 ng/ml, respectively) showed a wide scatter and were inversely related to age. In patients receiving MTX, concentrations of these metabolites were higher than in the untreated group, again reaching a peak in patients just completing 2 years of treatment (median HVA 110 ng/ml, 5HIAA 34 ng/ml). These results provide no support for the idea that neurotransmitter amine deficiency occurs in children with ALL receiving MTX, and indicate, rather, that amine and biopterin synthesis increases in such patients.
Keyword Pediatrics
Pediatrics
PEDIATRICS
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: ResearcherID Downloads
ResearcherID Downloads - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:18:38 EST by System User